Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.05
ARNA's Cash to Debt is ranked higher than
65% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. ARNA: 3.05 )
ARNA' s 10-Year Cash to Debt Range
Min: 0.46   Max: 11204.39
Current: 3.05

0.46
11204.39
Equity to Asset 0.31
ARNA's Equity to Asset is ranked higher than
54% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ARNA: 0.31 )
ARNA' s 10-Year Equity to Asset Range
Min: 0.07   Max: 0.98
Current: 0.31

0.07
0.98
F-Score: 2
Z-Score: -2.29
M-Score: 9.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -28.18
ARNA's Operating margin (%) is ranked higher than
76% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. ARNA: -28.18 )
ARNA' s 10-Year Operating margin (%) Range
Min: -2405.23   Max: -28.18
Current: -28.18

-2405.23
-28.18
Net-margin (%) -23.88
ARNA's Net-margin (%) is ranked higher than
75% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ARNA: -23.88 )
ARNA' s 10-Year Net-margin (%) Range
Min: -2421.99   Max: -23.88
Current: -23.88

-2421.99
-23.88
ROE (%) -21.16
ARNA's ROE (%) is ranked higher than
72% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ARNA: -21.16 )
ARNA' s 10-Year ROE (%) Range
Min: -1034.12   Max: -2.55
Current: -21.16

-1034.12
-2.55
ROA (%) -5.72
ARNA's ROA (%) is ranked higher than
78% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. ARNA: -5.72 )
ARNA' s 10-Year ROA (%) Range
Min: -205.44   Max: -2.49
Current: -5.72

-205.44
-2.49
ROC (Joel Greenblatt) (%) -29.64
ARNA's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. ARNA: -29.64 )
ARNA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -379.7   Max: -29.64
Current: -29.64

-379.7
-29.64
Revenue Growth (%) 35.10
ARNA's Revenue Growth (%) is ranked higher than
94% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ARNA: 35.10 )
ARNA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 35.1
Current: 35.1

0
35.1
EBITDA Growth (%) -70.30
ARNA's EBITDA Growth (%) is ranked higher than
50% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ARNA: -70.30 )
ARNA' s 10-Year EBITDA Growth (%) Range
Min: -70.3   Max: 74.6
Current: -70.3

-70.3
74.6
EPS Growth (%) -57.10
ARNA's EPS Growth (%) is ranked higher than
54% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. ARNA: -57.10 )
ARNA' s 10-Year EPS Growth (%) Range
Min: -57.1   Max: 104.7
Current: -57.1

-57.1
104.7
» ARNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ARNA Guru Trades in Q3 2013

Murray Stahl 45,000 sh (unchged)
Steven Cohen Sold Out
» More
Q4 2013

ARNA Guru Trades in Q4 2013

Ken Fisher 11,000 sh (New)
Paul Tudor Jones 45,133 sh (New)
Steven Cohen 500,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
» More
Q1 2014

ARNA Guru Trades in Q1 2014

Ken Fisher 11,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

ARNA Guru Trades in Q2 2014

Jim Simons 57,355 sh (New)
Ken Fisher 11,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.74
ARNA's P/B is ranked lower than
51% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ARNA: 8.74 )
ARNA' s 10-Year P/B Range
Min: 0.63   Max: 29.43
Current: 8.74

0.63
29.43
P/S 30.30
ARNA's P/S is ranked lower than
58% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. ARNA: 30.30 )
ARNA' s 10-Year P/S Range
Min: 7.58   Max: 106
Current: 30.3

7.58
106
EV-to-EBIT -8.30
ARNA's EV-to-EBIT is ranked higher than
59% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARNA: -8.30 )
ARNA' s 10-Year EV-to-EBIT Range
Min: 1.7   Max: 1106.8
Current: -8.3

1.7
1106.8
Current Ratio 3.98
ARNA's Current Ratio is ranked higher than
73% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. ARNA: 3.98 )
ARNA' s 10-Year Current Ratio Range
Min: 1.68   Max: 91.72
Current: 3.98

1.68
91.72
Quick Ratio 3.77
ARNA's Quick Ratio is ranked higher than
72% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ARNA: 3.77 )
ARNA' s 10-Year Quick Ratio Range
Min: 1.68   Max: 91.72
Current: 3.77

1.68
91.72

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.79
ARNA's Price/Tangible Book is ranked higher than
51% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. ARNA: 9.79 )
ARNA' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 25.66
Current: 9.79

0.62
25.66
Price/Median PS Value 1.44
ARNA's Price/Median PS Value is ranked higher than
58% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. ARNA: 1.44 )
ARNA' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 3.06
Current: 1.44

0.4
3.06
Earnings Yield (Greenblatt) 1982.20
ARNA's Earnings Yield (Greenblatt) is ranked higher than
97% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ARNA: 1982.20 )
ARNA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1996.5
Current: 1982.2

0.1
1996.5
Forward Rate of Return (Yacktman) -15.86
ARNA's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. ARNA: -15.86 )
ARNA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -52.2   Max: 1.4
Current: -15.86

-52.2
1.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RN3.Germany
Arena Pharmaceuticals, Inc. was incorporated on April 14, 1997, and commenced operations in July 1997. It is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. In June 2012, the US Food and Drug Administration, or FDA, approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with comorbidity or obese. It focuses on commercializing BELVIQ in the United States and ultimately in additional territories, selectively advancing its drug candidates and discovering additional drug candidates. The Company's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH, has provided Eisai Inc., or Eisai, exclusive rights to commercialize BELVIQ in the United States. It have also granted exclusive marketing and distribution rights for BELVIQ to Eisai for rest of North and South America and to Ildong Pharmaceutical Co., Ltd., or Ildong, for South Korea, subject to applicable regulatory approval in each of such territories. Its strategy is to focus on BELVIQ, advance its drug candidates and continue its research and development efforts. The Company competes successfully against these organizations, which include many large, well-financed and experienced pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FFDCA, and it's implementing regulations.
» More Articles for ARNA

Headlines

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
comment on ARNA Mar 15 2013 
comment on ARNA Mar 02 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

More From Other Websites
Sobha unveils Arena – encouraging you to step outside your carpet area Aug 20 2014
[video] Obesity treatment sales fall short Aug 18 2014
ARENA PHARMACEUTICALS INC Financials Aug 15 2014
News Release - Arena Offshore Project Award Aug 11 2014
Merko completes complicated Tondiraba Ice Arena in 14 months Aug 08 2014
ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 06 2014
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss Aug 04 2014
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 01 2014
Q2 2014 Arena Pharmaceuticals Earnings Release - After Market Close Aug 01 2014
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results Aug 01 2014
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results Aug 01 2014
Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3... Jul 30 2014
Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3... Jul 30 2014
Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for... Jul 29 2014
Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for... Jul 29 2014
Arena Sees Belviq Sales Climb Despite Seasonality Jul 25 2014
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on... Jul 25 2014
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on... Jul 25 2014
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 21 2014
Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in... Jul 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide